Travere Therapeutics, Inc. (TVTX) Stock Forecast
TVTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.73 / 5 from 15 analysts
- Price target
- $75.21 average of analyst targets
- Upside to target
- +51.6% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $0.05
- 52-week range
- $26.79 – $67.52
TVTX analyst ratings
15 analystsNumber of analysts at each rating.
TVTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TVTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.49 | −$0.57 | $1.16 | $0.59 | −17.0% | 8 |
| Current fiscal year (2026) | $1.69 | $0.96 | $2.95 | $0.91 | +86.2% | 8 |
| Next fiscal year (2027) | $5.64 | $3.50 | $6.95 | $1.69 | +232.8% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TVTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $195.7M | $157.2M | $240.0M | +18.7% | 14 |
| Current fiscal year (2026) | $724.6M | $634.7M | $806.7M | +47.6% | 14 |
| Next fiscal year (2027) | $1.08B | $882.7M | $1.36B | +49.4% | 14 |
TVTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TVTX revenue: reported and forecast
TVTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.40 | $0.50 | $0.51 | $0.52 | $0.49 | +23.7% | 2 up · 0 down |
| Current fiscal year (2026) | $1.87 | $1.76 | $1.74 | $1.74 | $1.69 | −9.3% | 1 up · 1 down |
| Next fiscal year (2027) | $4.85 | $5.49 | $5.67 | $5.67 | $5.64 | +16.2% | 3 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TVTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TVTX beat in 8 of 12.
What analysts expect from TVTX
15 analysts cover Travere Therapeutics; their consensus rating is strong buy (4.73 on a 1–5 scale, where 5 is a strong buy). The average price target is $75.21, 51.6% above the latest close of $49.60. Analysts expect earnings of $1.69 per share for 2026, +86.2% from a year earlier. For 2027 the average estimate is $5.64 per share on revenue of $1.1 billion. Travere Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: TVTX income statement, TVTX key metrics, TVTX chart. See the TVTX stock overview for the latest quote and news.
TVTX forecast FAQ
What is Travere Therapeutics's price target?
The average analyst price target for Travere Therapeutics is $75.21, 51.6% above the latest close of $49.60.
Is Travere Therapeutics a buy, hold or sell?
Of 15 analysts covering Travere Therapeutics, 12 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Travere Therapeutics's EPS forecast?
Analysts forecast $1.69 per share for 2026 (range $0.96 to $2.95); for 2027 the estimate is $5.64.
What is Travere Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $724.6 million, growth of 47.6%; for 2027 it is $1.1 billion.
When does Travere Therapeutics report earnings?
Travere Therapeutics is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes; the EPS estimate is $0.05.
Does Travere Therapeutics usually beat earnings estimates?
Travere Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.